Correlation Between Scopus Biopharma and ChitogenX
Can any of the company-specific risk be diversified away by investing in both Scopus Biopharma and ChitogenX at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Scopus Biopharma and ChitogenX into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Scopus Biopharma and ChitogenX, you can compare the effects of market volatilities on Scopus Biopharma and ChitogenX and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Scopus Biopharma with a short position of ChitogenX. Check out your portfolio center. Please also check ongoing floating volatility patterns of Scopus Biopharma and ChitogenX.
Diversification Opportunities for Scopus Biopharma and ChitogenX
0.46 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Scopus and ChitogenX is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Scopus Biopharma and ChitogenX in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ChitogenX and Scopus Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Scopus Biopharma are associated (or correlated) with ChitogenX. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ChitogenX has no effect on the direction of Scopus Biopharma i.e., Scopus Biopharma and ChitogenX go up and down completely randomly.
Pair Corralation between Scopus Biopharma and ChitogenX
If you would invest 10.00 in Scopus Biopharma on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Scopus Biopharma or generate 0.0% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 0.4% |
| Values | Daily Returns |
Scopus Biopharma vs. ChitogenX
Performance |
| Timeline |
| Scopus Biopharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
| ChitogenX |
Scopus Biopharma and ChitogenX Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Scopus Biopharma and ChitogenX
The main advantage of trading using opposite Scopus Biopharma and ChitogenX positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Scopus Biopharma position performs unexpectedly, ChitogenX can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChitogenX will offset losses from the drop in ChitogenX's long position.| Scopus Biopharma vs. Scpharmaceuticals | Scopus Biopharma vs. DiaMedica Therapeutics | Scopus Biopharma vs. Monopar Therapeutics | Scopus Biopharma vs. Pasithea Therapeutics Corp |
| ChitogenX vs. Therapeutic Solutions International | ChitogenX vs. Alpha Cognition | ChitogenX vs. Vg Life Sciences | ChitogenX vs. Adagene |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
| Stocks Directory Find actively traded stocks across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |